ReviewDiseases (Basel, Switzerland)2022
The Menace of
Review in Diseases (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.Emerging infectious diseases · 2026Article
- Article
- Fungi between threat and promise: global perspectives on health and innovation.Frontiers in microbiology · 2026Review
- Review
- Clinical correlates for fluconazole resistance inFrontiers in public health · 2026Article
- Accumulation of Trehalose 6-Phosphate in Candidozyma auris results in Decreased Echinocandin Resistance and Tolerance.Nature communications · 2025Article
- Genomic Dynamics of the EmergentOpen forum infectious diseases · 2025Article
- Risk Factors forInfection and drug resistance · 2025Article
- Geographical variation in the clinical profile of patients withAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Cerebrospinal Drain Infection byJournal of fungi (Basel, Switzerland) · 2024Review
- A simple and sensitive test forJournal of clinical microbiology · 2024Article
- Development of a standard evaluation method for microbial UV sensitivity using light-emitting diodes.Heliyon · 2024Article
- Pathogenesis, Prophylaxis, and Treatment ofBiomedicines · 2024Review
- The Gordian Knot ofPathogens (Basel, Switzerland) · 2023Review
- Description ofHealthcare (Basel, Switzerland) · 2023Article
- SevereJournal of intensive medicine · 2023Review
- Nanotechnology-Based Approaches for Voriconazole Delivery Applied to Invasive Fungal Infections.Pharmaceutics · 2023Review
- Candida auris: a novel emerging nosocomial pathogen - properties, epidemiological situation and infection control.GMS hygiene and infection control · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the causative agent for the Coronavirus Disease 2019 (COVID-19) pandemic, has sparked a medical emergency worldwide. With the rise in COVID-19 infections and an eventual increase in hospitalized critically ill patients, a trend of bacterial, fungal, and viral superinfection has been noted. One important agent of co-infection identified is
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.